General Catalyst’s Customer Value Fund will finance up to 70% of IM8 marketing spend as Prenetics raises full-year 2026 guidance to $210–220 million and targets more than $400 million in 2027 revenue.
Prenetics Global Limited said it closed $1 billion in growth financing from General Catalyst’s Customer Value Fund to support IM8, its direct-to-consumer wellness brand co-founded by David Beckham, while raising IM8’s full-year 2026 revenue guidance to $210–220 million from $190–210 million. The facility is structured to fund up to 70% of IM8’s marketing spend on a monthly customer-cohort basis, with General Catalyst receiving a capped share of income tied to the performance of those financed cohorts. Prenetics said the arrangement involves no equity, warrants, or convertible instruments, and once General Catalyst recovers its investment and capped return for a cohort, all later value from those customers belongs entirely to IM8. The company framed the deal as a no-dilution way to accelerate customer acquisition rather than a liquidity measure, adding that it had about $139.7 million in estimated cash balances, current financial assets measured at fair value through profit or loss, and cash consideration held in escrow and holdback as of May 31, 2026. IM8, launched in December 2024, has delivered more than 50 million servings, is shipping about 200,000 servings a day across 43 markets, and is generating an order every 27 seconds, according to the company. Prenetics said every $1 spent on customer acquisition has returned $1.44 in gross profit across mature cohorts, that June 2026 produced preliminary unaudited monthly revenue of about $17 million, and that IM8 is expected to reach a $300 million annualized run-rate by the end of 2026 and more than $400 million in full-year 2027 revenue. The company also said new launches are planned in Q4 2026 and Q1 2027, including IM8 Hydration and a premium gummies line, while two randomized controlled trials are underway on gut health and longevity.